Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | FYN | P06241 | 3/20 | 0.52 |
| ▸ | PIM1 | P11309 | 4/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.43 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | KIF5B | P33176 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ETV6 | P41212 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516153 | 0.82 | MAPT (0.45) | MAPTSMN1; SMN2LMNAPOLBMEN1 | |
| SCHEMBL3512920 | 0.80 | MAPT (0.55) | MAPTSMN1; SMN2LMNAPOLBMEN1 | |
| SCHEMBL1424073 | 0.75 | MAPT (0.74) | MAPTSMN1; SMN2LMNAPOLBMEN1 | |
| SCHEMBL4326781 | 0.72 | FYN (0.66) | MAPTSMN1; SMN2LMNAPOLBMEN1 | |
| SCHEMBL4558600 | 0.72 | FYN (0.74) | MAPTSMN1; SMN2LMNAPOLBMEN1 | |
| SCHEMBL4727573 | 0.72 | FYN (0.60) | MAPTSMN1; SMN2LMNAPOLBMEN1 | |
| SCHEMBL4333167 | 0.71 | PIK3CG (0.64) | MAPTSMN1; SMN2LMNAPOLBMEN1 | |
| SCHEMBL4333345 | 0.71 | PIM1 (0.71) | MAPTSMN1; SMN2LMNAPOLBMEN1 | |
| SCHEMBL3517867 | 0.71 | SCN5A (0.41) | MAPTSMN1; SMN2LMNAPOLBMEN1 | |
| SCHEMBL4338374 | 0.70 | PIK3CG (0.71) | MAPTSMN1; SMN2LMNAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155202-A2 | 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AND 3,5-DISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | claimed |
| WO-2008138889-A2 | 3, 6-DISUBSTITUTED-IMIDAZO [1, 2-B] PYRIDAZINES AND 3, 5-DISUBSTITUTED PYRAZOLO[1, 5-A] PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | claimed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| EP-2155202-A2 | 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AND 3,5-DISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138889-A2 | 3, 6-DISUBSTITUTED-IMIDAZO [1, 2-B] PYRIDAZINES AND 3, 5-DISUBSTITUTED PYRAZOLO[1, 5-A] PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | MAPT 4070/4885SMN1; SMN2 4827/4885LMNA 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.